RT Book, Section
A1 Kittleson, Michelle M.
A1 Patel, Jignesh K.
A1 Kobashigawa, Jon A.
A2 Fuster, Valentin
A2 Harrington, Robert A.
A2 Narula, Jagat
A2 Eapen, Zubin J.
SR Print(0)
ID 1161716891
T1 CARDIAC TRANSPLANTATION
T2 Hurst's The Heart, 14e
YR 2017
FD 2017
PB McGraw-Hill Education
PP New York, NY
SN 9780071843249
LK accesscardiology.mhmedical.com/content.aspx?aid=1161716891
RD 2024/04/24
AB Despite  major  advances  in  the  treatment  of  end-stage  heart  disease,  a  sizable  number  of  patients  with  refractory  heart  failure  (HF),  progressive  angina,  or  uncontrolled  ventricular  arrhythmias  cannot  be  stabilized  with  medical  or  interventional/surgical  therapy  and  suffer  significant  morbidity  and  mortality.1  In  these  patients,  biological  replacement  of  the  heart  (cardiac  transplantation)  has  become  standard  therapy  and  is  widely  accepted  to  improve  quality  and  quantity  of  life  in  carefully  selected  patients.  As  technologic  and  engineering  advances  occur,  support  or  replacement  of  the  heart  by  mechanical  devices  (mechanical  circulatory  support  [MCS])  offers  additional  options  for  patients  with  end-stage  heart  disease  as  a  bridge  to  recovery,  bridge  to  transplantation,  or  destination  therapy.